Ideaya Biosciences (IDYA) closed at $31.24 on November 6, 2026, up 1.9% from the previous close, on volume of 1,546,343 shares (30-day average 894,869).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Leerink Partners Sticks to Their Hold Rating for IDEAYA Biosciences (IDYA)
TipRanks (Thu, 5-Nov 9:31 AM ET)
Citi Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
TipRanks (Thu, 5-Nov 6:57 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 4-Nov 8:40 AM ET)
TipRanks (Wed, 4-Nov 8:30 AM ET)
IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events
PRNewswire (Wed, 4-Nov 6:00 AM ET)
IDEAYA Biosciences GAAP EPS of -$1.22 misses by $0.03, revenue of $10.24M beats by $2.66M
Seeking Alpha News (Tue, 3-Nov 6:09 AM ET)
PRNewswire (Tue, 3-Nov 6:00 AM ET)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Fri, 30-Oct 6:00 AM ET)
IDYA highlights IDE849 Phase 1 update with 17.4-month median overall survival in second-line SCLC
Market Chameleon (Mon, 26-Oct 7:42 AM ET)
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ideaya Biosciences trades on the NASDAQ stock market under the symbol IDYA.
As of November 6, 2026, IDYA stock price climbed to $31.24 with 1,546,343 million shares trading.
IDYA has a beta of 0.73, meaning it tends to be less sensitive to market movements. IDYA has a correlation of 0.05 to the broad based SPY ETF.
IDYA has a market cap of $3.01 billion. This is considered a Mid Cap stock.
Last quarter Ideaya Biosciences reported $10 million in Revenue and -$1.22 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.04.
In the last 3 years, IDYA traded as high as $47.74 and as low as $13.45.
The top ETF exchange traded funds that IDYA belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
IDYA has underperformed the market in the last year with a price return of +4.7% while the SPY ETF gained +10.8%. IDYA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.8% and -10.0%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
IDYA support price is $29.69 and resistance is $31.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IDYA shares will trade within this expected range on the day.
